Stuart R. Chipkin

Stuart R. Chipkin

Auto-generated profile, based on publicly available information

Stuart R. Chipkin

Department of Kinesiology University of Massachusetts Amherst Amherst Massachusetts USA

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2004 in Circulation
Verified
Journal Article
Open access
PDF file
HLHarold L. Lazar
Harold L. Lazar
SCStuart R. Chipkin
Stuart R. Chipkin
CFCarmel A. Fitzgerald
Carmel A. Fitzgerald
YBYusheng Bao
Yusheng Bao
HCHoward J Cabral
Howard J Cabral
CACarl S. Apstein
Carl S. Apstein
Background— This study sought to determine whether tight glycemic control with a modified glucose-insulin-potassium (GIK) solution in diabetic coronary artery bypass graft (CABG) patients would improve perioperative outcomes. Methods and Results— One hundred forty-one diabetic patients undergoing CABG were prospectively randomized to tight glycemic control (serum glucose, 125 to 200 mg/dL) with GIK or standard therapy (serum glucose <250 mg/dL) using intermittent subcutaneous insulin beginning before anesthesia and continuing for 12 hours after surgery. GIK patients had lower serum glucose levels (138±4 versus 260±6 mg/dL; P <0.0001), a lower incidence of atrial fibrillation (16.6% versus 42%; P =0.0017), and a shorter postoperative length of stay (6.5±0.1 versus 9.2±0.3 days; P =0.003). GIK patients also showed a survival advantage over the initial 2 years after surgery ( P =0.04) and decreased episodes of recurrent ischemia (5% versus 19%; P =0.01) and developed fewer recurrent wound infections (1% versus 10%, P =0.03). Conclusions— Tight glycemic control with GIK in diabetic CABG patients improves perioperative outcomes, enhances survival, and decreases the incidence of ischemic events and wound complications.

1 January 2013 in Circulation
Verified
Journal Article
Closed access
PDF file
BPBeth A. Parker
Beth A. Parker
JCJeffrey A. Capizzi
Jeffrey A. Capizzi
AGAdam S. Grimaldi
Adam S. Grimaldi
PCPriscilla M. Clarkson
Priscilla M. Clarkson
SCStephanie M. Cole
Stephanie M. Cole
PTPaul D. Thompson
Paul D. Thompson
Background—: Many clinicians believe that statins cause muscle pain, but this has not been observed in clinical trials, and the effect of statins on muscle performance has not been carefully studied. Methods and Results—: The Effect of Statins on Skeletal Muscle Function and Performance (STOMP) study assessed symptoms and measured creatine kinase, exercise capacity, and muscle strength before and after atorvastatin 80 mg or placebo was administered for 6 months to 420 healthy, statin-naive subjects. No individual creatine kinase value exceeded 10 times normal, but average creatine kinase increased 20.8±141.1 U/L ( P <0.0001) with atorvastatin. There were no significant changes in several measures of muscle strength or exercise capacity with atorvastatin, but more atorvastatin than placebo subjects developed myalgia (19 versus 10; P =0.05). Myalgic subjects on atorvastatin or placebo had decreased muscle strength in 5 of 14 and 4 of 14 variables, respectively ( P =0.69). Conclusions—: These results indicate that high-dose atorvastatin for 6 months does not decrease average muscle strength or exercise performance in healthy, previously untreated subjects. Nevertheless, this blinded, controlled trial confirms the undocumented impression that statins increase muscle complaints. Atorvastatin also increased average creatine kinase, suggesting that statins produce mild muscle injury even among asymptomatic subjects. This increase in creatine kinase should prompt studies examining the effects of more prolonged, high-dose statin treatment on muscular performance. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00609063.

1 February 2009 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
HLHarold L Lazar
Harold L Lazar
MMMarie McDonnell
Marie McDonnell
SCStuart R Chipkin
Stuart R Chipkin
AFAnthony P Furnary
Anthony P Furnary
RERichard M Engelman
Richard M Engelman
SFSociety Of Thoracic Surgeons Blood Glucose Guideline Task Force
Society Of Thoracic Surgeons Blood Glucose Guideline Task Force

9 December 2011 in Diabetes Care
Verified
Journal Article
Open access
Steven K. MalinSteven K. Malin
Steven K. Malin
RGRobert Gerber
Robert Gerber
SCStuart R. Chipkin
Stuart R. Chipkin
BBBarry Braun
Barry Braun
OBJECTIVE: Physical activity or metformin enhances insulin sensitivity and opposes the progression from prediabetes to type 2 diabetes. The combination may be more effective because each treatment stimulates AMP-activated protein kinase activity in skeletal muscle. We evaluated the effects of exercise training plus metformin on insulin sensitivity in men and women with prediabetes, compared with each treatment alone. RESEARCH DESIGN AND METHODS: For 12 weeks, men and women with prediabetes were assigned to the following groups: placebo (P), 2,000 mg/day metformin (M), exercise training with placebo (EP), or exercise training with metformin (EM) (n = 8 per group). Before and after the intervention, insulin sensitivity was measured by euglycemic hyperinsulinemic (80 mU/m2/min) clamp enriched with [6,6-2H]glucose. Changes due to intervention were compared across groups by repeated-measures ANOVA. RESULTS: All three interventions increased insulin sensitivity (P < 0.05) relative to the control group. The mean rise was 25–30% higher after EP than after either EM or M, but this difference was not significant. CONCLUSIONS: Insulin sensitivity was considerably higher after 12 weeks of exercise training and/or metformin in men and women with prediabetes. Subtle differences among condition means suggest that adding metformin blunted the full effect of exercise training.

17 January 2019 in International Journal of Behavioral Nutrition and Physical Activity
Verified
Journal Article
Open access
PDF file
CTCatrine Tudor-Locke
Catrine Tudor-Locke
EAElroy Aguiar
Elroy Aguiar
HHHo Han
Ho Han
SDScott Ducharme
Scott Ducharme
JSJohn Schuna
John Schuna
JSJohn Staudenmayer
John Staudenmayer
Previous studies have reported that walking cadence (steps/min) is associated with absolutely-defined intensity (metabolic equivalents; METs), such that cadence-based thresholds could serve as reasonable proxy values for ambulatory intensities. To establish definitive heuristic (i.e., evidence-based, practical, rounded) thresholds linking cadence with absolutely-defined moderate (3 METs) and vigorous (6 METs) intensity. In this laboratory-based cross-sectional study, 76 healthy adults (10 men and 10 women representing each 5-year age-group category between 21 and 40 years, BMI = 24.8 ± 3.4 kg/m2) performed a series of 5-min treadmill bouts separated by 2-min rests. Bouts began at 0.5 mph and increased in 0.5 mph increments until participants: 1) chose to run, 2) achieved 75% of their predicted maximum heart rate, or 3) reported a Borg rating of perceived exertion > 13. Cadence was hand-tallied, and intensity (METs) was measured using a portable indirect calorimeter. Optimal cadence thresholds for moderate and vigorous ambulatory intensities were identified using a segmented regression model with random coefficients, as well as Receiver Operating Characteristic (ROC) models. Positive predictive values (PPV) of candidate heuristic thresholds were assessed to determine final heuristic values. Optimal cadence thresholds for 3 METs and 6 METs were 102 and 129 steps/min, respectively, using the regression model, and 96 and 120 steps/min, respectively, using ROC models. Heuristic values were set at 100 steps/min (PPV of 91.4%), and 130 steps/min (PPV of 70.7%), respectively. Cadence thresholds of 100 and 130 steps/min can serve as reasonable heuristic thresholds representative of absolutely-defined moderate and vigorous ambulatory intensity, respectively, in 21–40 year olds. These values represent useful proxy values for recommending and modulating the intensity of ambulatory behavior and/or as measurement thresholds for processing accelerometer data. Clinicaltrials.gov ( NCT02650258 ).

1 June 2008 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
NANancy A. Allen
Nancy A. Allen
JFJames A. Fain
James A. Fain
BBBarry Braun
Barry Braun
SCStuart R. Chipkin
Stuart R. Chipkin